期刊文献+

孟鲁司特钠辅助治疗成人支气管哮喘的临床价值分析 被引量:3

Analysis of the clinical value of montelukast sodium in the adjuvant treatment of adult bronchial asthma
暂未订购
导出
摘要 目的分析孟鲁司特钠辅助治疗成人支气管哮喘的临床价值。方法100例成人支气管哮喘患者,按照随机数字表法分为观察组与对照组,每组50例。对照组患者采用常规治疗,观察组患者采用孟鲁司特钠辅助治疗。对比两组患者的肺功能指标[第1秒用力呼气容积(FEV1)、FEV1/用力肺活量(FVC)、呼气峰流速(PEF)]、临床疗效、不良反应发生情况。结果观察组FEV1(2.7±0.6)L、FEV1/FVC(89.5±7.5)%、PEF(358.4±40.9)L/min均高于对照组的(1.5±0.3)L、(64.5±6.5)%、(312.4±40.5)L/min,差异有统计学意义(P<0.05)。观察组治疗总有效率为92.0%,高于对照组的70.0%,差异有统计学意义(P<0.05)。观察组不良反应发生率为8.0%,与对照组的24.0%对比,差异无统计学意义(P>0.05)。结论成人支气管哮喘采用孟鲁司特钠辅助治疗的效果十分显著,能够促进肺功能指标改善,提高临床疗效,减少不良反应产生,具有较高的安全性与有效性,值得积极推广应用。 Objective To analyze the clinical value of montelukast sodium in the adjuvant treatment of adult bronchial asthma.Methods A total of 100 adult patients with bronchial asthma were divided into observation group and control group according to the random numerical table,with 50 cases in each group.The control group received conventional treatment,and the observation group received montelukast sodium adjuvant therapy.The pulmonary function indexes[forced expiratory volume in the 1st second(FEV1),FEV1/forced vital capacity(FVC),peak expiratory flow(PEF)],clinical efficacy and occurrence of adverse reactions were compared between the two groups.Results The FEV1(2.7±0.6)L,FEV1/FVC(89.5±7.5)%,PEF(358.4±40.9)L/min in the observation group were higher than(1.5±0.3)L,(64.5±6.5)%,(312.4±40.5)L/min in the control group,and the differences were statistically significant(P<0.05).The total effective rate of treatment in the observation group was 92.0%,which was higher than 70.0%in the control group,and the difference was statistically significant(P<0.05).The incidence of adverse reactions in the observation group was 8.0%,and the difference was not statistically significant compared with 24.0%in the control group(P>0.05).Conclusion Montelukast sodium has a very significant effect in adjuvant treatment of adult bronchial asthma,which can promote the improvement of pulmonary function indexes,improve clinical efficacy,reduce occurrence of adverse reactions,and has high safety and effectiveness.It is worthy of active promotion and application.
作者 姜艳霞 JIANG Yan-xia(Department of Respiratory Medicine,Liaoning Provincial People's Hospital,Shenyang 110000,China)
出处 《中国实用医药》 2022年第21期111-113,共3页 China Practical Medicine
关键词 成人 支气管哮喘 孟鲁司特钠 肺功能 辅助治疗 临床疗效 Adult Bronchial asthma Montelukast sodium Pulmonary function Adjuvant therapy Clinical efficacy
  • 相关文献

二级参考文献45

同被引文献38

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部